Strengthening Health Innovation and Biotechnology in the EU

Biotechnology has become one of the European Union’s most strategic sectors, driving innovation, economic growth, high-skilled employment, and global competitiveness. More importantly, it is transforming healthcare by enabling the development of advanced therapies, innovative diagnostics, personalised medicine, and new approaches to disease prevention and treatment. As Europe faces demographic change, rising healthcare needs, and increasing global competitiveness, biotechnology is emerging as a key pillar of both public health and economic resilience.

The strategic importance of biotechnology has been reinforced by recent geopolitical developments, including the COVID-19 pandemic, disruptions to global supply chains and growing competition in critical technologies. These challenges have highlighted the need for Europe to strengthen its capacity to develop, manufacture and deploy health technologies within the Union. Biotechnology is therefore increasingly recognised not only as an innovation sector but also as a critical component of Europe’s strategic autonomy and health security.

This ambition is closely aligned with the vision set out in the Letta and Draghi reports. Both reports emphasise the need to strengthen Europe’s competitiveness by deepening the Single Market, reducing fragmentation, fostering innovation and creating conditions for strategic industries to scale up within Europe. They stress that Europe must better convert its scientific excellence into industrial leadership and societal benefit, particularly in sectors such as biotechnology which are essential for future prosperity, resilience and technological sovereignty.

Despite Europe’s strong scientific base and high regulatory standards, the biotechnology sector continues to face significant challenges. One of the most persistent obstacles is the fragmented implementation of EU legislation across Member States. Variations in regulatory interpretation and administrative procedures often create delays, increase compliance costs and reduce predictability for innovators.

These difficulties are particularly evident in the health sector. Many innovative products combine medicinal products, medical devices and diagnostic technologies, requiring developers to navigate multiple regulatory frameworks and approval pathways. Such complexity can slow clinical development, delay patient access to innovative treatments and reduce Europe’s attractiveness as a destination for clinical research and investment.

Recognising these challenges, the European Commission adopted the European Biotech Act in December 2025 as a strategic initiative to modernise and streamline the biotechnology regulatory framework. This Act seeks to strengthen Europe’s biotechnology and biomanufacturing ecosystem by improving access to funding, supporting innovation and creating a more coherent and predictable regulatory environment.

A core objective of the Act is the simplification and harmonisation of clinical trial procedures. Proposed measures include faster approval of timelines, harmonised assessment and submission requirements, improved cooperation among regulatory authorities and the introduction of a single core dossier to reduce duplication and administrative burden.

These reforms are expected to accelerate the development of innovative therapies while maintaining the EU’s high standards of safety, ethics and patient protection.

The health dimension of the Biotech Act is particularly significant. Advanced therapies, including gene therapies, cell therapies, RNA-based medicines, and other cutting-edge technologies, offer unprecedented opportunities for patients suffering from serious, rare, or currently untreatable diseases.

To facilitate their development and market entry, the Act promotes earlier and more continuous dialogue between developers, regulators, and health technology assessment bodies. This approach aims to reduce regulatory uncertainty, support the generation of evidence, and ultimately accelerate patient access to breakthrough innovations.

Beyond healthcare, the Act introduces a more science-based and risk-proportionate regulatory approach across biotechnology applications. This is particularly relevant for genetically modified micro-organisms, where requirements are increasingly tailored to the level of risk involved. By distinguishing between low-risk and higher-risk activities, the EU seeks to ensure efficient and proportionate oversight while maintaining strong safeguards for public health, environmental protection, and biosecurity.

The Act also seeks to support innovation in the food and bioeconomy sectors through improved regulatory guidance and more efficient authorisation procedures. While these measures can help bring innovative products to market more quickly, public trust, ethical considerations and societal acceptance will remain essential factors in ensuring the successful uptake of new technologies.

Recognising the strategic importance of biotechnology for Europe’s future, the Cyprus Presidency has placed health innovation and biotechnology high on its agenda. In line with its priorities of competitiveness, resilience, innovation and strategic autonomy, the Presidency has advanced discussions on the Biotech Act package and promoted measures to strengthen Europe’s biotechnology and biomanufacturing sectors.

Through its work in the Council and within the EPSCO configuration, the Presidency is contributing to the development of a modern regulatory framework capable of supporting innovation while safeguarding public health. This complements broader efforts to reinforce resilience of healthcare systems and pharmaceutical supply chains, including the provisional agreement reached by the Cyprus Presidency with the European Parliament on Critical Medicines Act. Together, these initiatives support the Union’s objectives of strengthening health security, reducing strategic dependencies and ensuring access to innovative and essential medicines.

Strengthening health innovation and biotechnology is essential for Europe’s competitiveness, resilience and technological leadership. By reducing regulatory fragmentation, supporting clinical research and accelerating the development of advanced health technologies, the European Biotech Act can translate scientific excellence into tangible benefits for patients and healthcare systems. In doing so, it advances the vision set out in the Letta and Draghi reports for a more competitive, innovative and strategically autonomous Health Union.